Aisling raises $650 million for new fund
This article was originally published in Scrip
Executive Summary
The private equity firm Aisling Capital has raised $650 million for a new life sciences fund, Aisling Capital III. The New York-based company will invest primarily in companies developing pharmaceutical, biopharmaceutical and medical products, but also in those that provide drug development, manufacturing and other services to the pharmaceutical industry. One of Aisling's investor companies, Map Pharmaceuticals, signed a $900 million co-development and commercialisation deal with AstraZeneca last month for Map's unit dose budesonide (Scrip Online, December 22nd, 2008).